Evidence map›Paper›PMID 35084992›Full record

ReviewAnnual review of medicine2022

Clinical Phenotypes of Cystic Fibrosis Carriers.

Philip M Polgreen, Alejandro P Comellas

Abstract readReview
In one paragraph

Review in Annual review of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. A test of automated use of electronic health records to aid in diagnosis of genetic disease.Genetics in medicine : official journal of the American College of Medical Genetics · 2023
    Article
  17. Analysis ofViruses · 2023
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Philip M PolgreenDivision of Infectious Diseases, Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA; email: philip-polgreen@uiowa.edu.
Alejandro P ComellasDivision of Pulmonary and Critical Care, Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA; email: alejandro-comellas@uiowa.edu.

Funding

Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
The University of Iowa Clinical and Translational Science AwardUL1TR002537 · NCATS · UNIVERSITY OF IOWA · PI HANSEN, MARLAN R, WINOKUR, PATRICIA · 2018 to 2022
$20.0M
Estimating the risk for and severity of respiratory infections attributable to CFTR heterozygosityR01AI143671 · NIAID · UNIVERSITY OF IOWA · PI POLGREEN, PHILIP M · 2021 to 2025
$3.7M
NCATS NIH HHS UL1 TR002537NIAID NIH HHS R01 AI143671NIDDK NIH HHS P30 DK054759
6 · The paper itself

Abstract

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in

Indexed as

Cystic FibrosisFemaleGenetic TestingHeterozygoteHumansInfant, NewbornMutationNeonatal ScreeningPhenotypePregnancycarrierCFTRcystic fibrosis

Identifiers

PMID35084992
PMCPMC8884701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.